Abstract |
Three major modes of cancer therapy (surgery, radiation and chemotherapy) are the mainstay of modern oncologic therapy. To minimize the side effects of these therapies, molecular-targeted cancer therapies, including armed antibody therapy, have been developed with limited success. In this study, we have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was induced immediately after irradiating mAb-IR700-bound target cells with NIR light. We observed in vivo tumor shrinkage after irradiation with NIR light in target cells expressing the epidermal growth factor receptor. The mAb-IR700 conjugates were most effective when bound to the cell membrane and produced no phototoxicity when not bound, suggesting a different mechanism for PIT as compared to conventional photodynamic therapies. Target-selective PIT enables treatment of cancer based on mAb binding to the cell membrane.
|
Authors | Makoto Mitsunaga, Mikako Ogawa, Nobuyuki Kosaka, Lauren T Rosenblum, Peter L Choyke, Hisataka Kobayashi |
Journal | Nature medicine
(Nat Med)
Vol. 17
Issue 12
Pg. 1685-91
(Nov 06 2011)
ISSN: 1546-170X [Electronic] United States |
PMID | 22057348
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Chemical References |
- Antibodies, Monoclonal
- Photosensitizing Agents
- ErbB Receptors
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Cell Line, Tumor
(drug effects)
- Cell Proliferation
- ErbB Receptors
(immunology, metabolism)
- Female
- Humans
- Immunotherapy
- Mice
- Mice, Nude
- Microscopy, Fluorescence
- NIH 3T3 Cells
- Neoplasms
(therapy)
- Photochemotherapy
(methods)
- Photosensitizing Agents
(therapeutic use)
- Xenograft Model Antitumor Assays
|